Pharmaceutical

IBI-322 by Innovent Biologics for Lymphoma: Likelihood of Approval

IBI-322 is under clinical development by Innovent Biologics and currently in Phase I for Lymphoma.

Dec 22, 2023 - 18:00
IBI-322 is under clinical development by Innovent Biologics and currently in Phase I for Lymphoma.
Read the original article

Tags:

Previous Article

Opinion: The U.S. must raise federal alcohol taxes to address the alarming rise ...

Next Article

Volrustomig by AstraZeneca for Cervical Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Newly launched Calluna raises $81m to advance monoclonal antibody pipeline

Newly launched Calluna raises $81m to advance monoclona...

Jan 23, 2024

ILution travoprost by Glaukos for Open-Angle Glaucoma: Likelihood of Approval

ILution travoprost by Glaukos for Open-Angle Glaucoma: ...

Jun 20, 2024

STAT+: AI can speed up drug discovery but don’t expect it to cure cancer, yet

STAT+: AI can speed up drug discovery but don’t expect ...

Feb 7, 2024